Related Experiment Video
Updated: Mar 6, 2026
08:30
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
3.3K
Innovations in cardiac transplantation
Reema Hasan1, Ashraf Abou El Ela, Daniel Goldstein
1aDepartment of Internal Medicine/Cardiovascular Medicine bDepartment of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan, USA.
Current Opinion in Cardiology
|March 18, 2017
Summary
Future heart transplantation focuses on increasing organ donors through donation after cardiac death and novel preservation methods. Emerging biomarkers and therapies aim to improve graft surveillance and long-term patient outcomes.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- Growing prevalence of heart failure necessitates advancements in cardiac transplantation.
- Current strategies focus on organ procurement, graft surveillance, and therapeutic outcomes.
Purpose of the Study:
- To review recent advancements in organ procurement for heart transplantation.
- To discuss emerging graft surveillance techniques and novel therapeutic strategies.
- To highlight future directions for improving cardiac transplant outcomes.
Main Methods:
- Review of preliminary studies on donation after cardiac death.
- Analysis of novel organ preservation techniques, including ex-vivo perfusion.
- Evaluation of emerging biomarkers for acute graft rejection.
- Investigation into novel immunosuppressants and therapeutics for chronic allograft vasculopathy.
Main Results:
- Donation after cardiac death shows potential to expand the donor pool.
- Ex-vivo perfusion may enhance donor organ viability.
- Circulating-free DNA is a potential biomarker for acute graft rejection, replacing endomyocardial biopsy.
- No definitive risk-predictive biomarker for heart transplantation is currently available.
- Novel immunosuppressants and therapeutics for chronic allograft vasculopathy are under investigation.
Conclusions:
- Advancements in organ procurement and preservation are crucial for expanding the donor pool.
- Biomarkers and novel therapeutics hold promise for improving graft surveillance and long-term outcomes.
- Ongoing clinical trials are essential to validate these advancements and improve survival rates in cardiac transplantation.
